Back to: FDA ADEPT 10: Addressing Challenges in Neonatal Product Development
Introductory Remarks for Panel Discussions and Moderator
Dalia Feltman, MD, MA
OPT/OCMO/OC, FDA
Panel A: Weighing benefits and risks when evidence is limited
Panelists:
Alison Bateman-House PhD, MPH, MA
NYU Grossman School of Medicine
Robert Nelson, MD, PhD
Johnson and Johnson
Allyson Berent, DVM, DACVIM
The Foundation for Angelman Syndrome Therapeutics (FAST)
Elliott Mark Weiss, MD, MSME
Seattle Children’s Hospital
Matthew A. Rysavy, MD, PhD
McGovern Medical School at UTHealth Houston
Ashley O’Neil, CRNP
It’s a NICU World
Panel B: Study design considerations
Panelists:
Alison Bateman-House PhD, MPH, MA
NYU Grossman School of Medicine
Robert Nelson, MD, PhD
Johnson and Johnson
Lindsey Wahlstrom, MPH, CPH
Rona’s FUN LAB
Elliott Mark Weiss, MD, MSME
Seattle Children’s Hospital
Matthew A. Rysavy, MD, PhD
McGovern Medical School at UTHealth Houston
Jennifer Degl, MS
NICU Parent Network